Abstracts tagged "T cells"

Abstract Number: 1640 • 2013 ACR/ARHP Annual Meeting
Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis
Maja Bulatovic Calasan¹, S.J. Vastert², Rianne C. Scholman³, Frederik Verweij³, Mark Klein³, Nico M. Wulffraat⁴, Berent J. Prakken³ and Femke van Wijk³, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The balance between regulatory (Treg) and effector T cells (Teff) is crucial for immune regulation in juvenile idiopathic arthritis (JIA). How methotrexate (MTX), the…
Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting
Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber³ and J.a.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
Abstract Number: 2431 • 2013 ACR/ARHP Annual Meeting
Association Of T Follicular Helper / Th17 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists
Marc C. Levesque¹, Camilla Macedo², Lisa Boyette², Kevin Hadi³, Erich R Wilkerson⁴, Diana Metes², Larry W. Moreland⁵ and Mandy J. McGeachy⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Univeristy of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine, Division of Rheumatology and Clinical Immunology, Univeristy of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoreactive memory B cells and T cells contribute to the pathogenesis of rheumatoid arthritis (RA) through production of antibodies and cytokines that activate monocytes…
Abstract Number: 1641 • 2013 ACR/ARHP Annual Meeting
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt², Anja Feldmann², Irene Michalk², Claudia C. Bippes², Nicole Berndt², Anne Hermsdorf², Slava Stamova², Biji T. Kurien³, Robert Hal Scofield⁴, A. Darise Farris⁵, Judith A. James⁶, Holger Bartsch⁷ and Michael Bachmann², ¹Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
Abstract Number: 722 • 2013 ACR/ARHP Annual Meeting
BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice
Song Guo Zheng¹, Maogeng Chen¹, Qiang Li² and William Stohl³, ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF (B cell activating factor belonging to the TNF family) promotes B cells maturation in germinal center. The generation of germinal center depends on…
Abstract Number: 2411 • 2013 ACR/ARHP Annual Meeting
The Peripheral Blood T Cell Repertoire Before The Clinical Onset Of Rheumatoid Arthritis – a Study Of Incident Cases and Controls
Carl Turesson¹, Ulf Bergström², Edgars Grins³, Olle Melander⁴, Lennart Truedsson⁵, Lennart Jacobsson² and Stefan Jovinge³, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden, ⁴Unit of Hypertension and Cardiovascular Disease, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden
Background/Purpose: Previous studies indicate that circulating antibodies may be detected in individuals who later develop rheumatoid arthritis (RA) years before onset, and T cells have…
Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting
T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Odilia B.J. Corneth¹, Zana Brkic², Cornelia G. van Helden-Meeuwsen³, Radboud J.E.M. Dolhain⁴, Naomi I. Maria³, Sandra M.J. Paulissen⁴, Nadine Davelaar⁵, Jan Piet van Hamburg⁵, Paul L. Van Daele³, Virgil A. Dalm², Martin van Hagen³, Marjan A. Versnel² and Erik Lubberts⁶, ¹Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…
Abstract Number: 723 • 2013 ACR/ARHP Annual Meeting
Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4⁺t Cells
Agapitos Patakas¹, Rui-Ru Ji², William Weir³, Sean Connolly², Steven G. Nadler², James M. Brewer⁴, Iain B. McInnes⁴ and Paul Garside⁴, ¹Institute of Infection, Immunology and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Immunology and Inflammation, Bristol Myers Squibb Co. Research and Development, Princeton, NJ, ³Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Absence of co-stimulation in the presence of TCR-stimulation has been proposed to induce tolerance via deletion or anergy. Abatacept is a CTLA-4-Ig molecule that…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…
Abstract Number: 1156 • 2013 ACR/ARHP Annual Meeting
Suppression Of Immune Responses and Joint Inflammation By Myeloid-Derived Suppressor Cells In a T Cell-Dependent Mouse Model Of Rheumatoid Arthritis
Katalin Mikecz¹, Julia Kurko¹, Timea Ocsko¹, Andras Vida¹, Beata Tryniszewska¹, Tibor A. Rauch¹, Joel A. Block², Robert S. Katz³, Anjali Nair², Carla R. Scanzello⁴ and Tibor T. Glant¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush Medical College, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of innate immune cells with immunosuppressive properties. We previously identified MDSCs in the synovial fluid (SF)…
Abstract Number: 724 • 2013 ACR/ARHP Annual Meeting
Dose-Dependent Suppression Of Cytokine Production From T Cells By a Novel Phosphoinositide 3-Kinase Delta Inhibitor
Emily E. Way¹, Kong Chen², Kamal D. Puri³ and Jay K. Kolls², ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Gilead Sciences, Inc., Seattle, WA
Background/Purpose: The use of specific cytokine inhibitors to treat inflammatory autoimmune conditions is common but typically utilizes monoclonal antibodies, fusion proteins, and other molecules whose…
Abstract Number: 2221 • 2013 ACR/ARHP Annual Meeting
The Histamine H₄ Receptor Drives Inflammation In Preclinical Models Of Arthritis
Paul J. Dunford¹, Jeffery Cowden², Fuqu Yu², Homayon Banie², Mandana Farahani², Ping Ling², Steven Nguyen², Jason Riley², Mai Zhang², Jian Zhu² and Robin L. Thurmond², ¹Immunology, Janssen R&D, LLC, San Diego, CA, ²Janssen R&D, LLC, San Diego, CA
Background/Purpose: The histamine H4 receptor (H4R) has been shown to drive inflammatory responses in models of asthma, colitis and dermatitis and in these models it…
Abstract Number: 1172 • 2013 ACR/ARHP Annual Meeting
Molecular Characterisation Of The Killer Cell Immunoglobulin-Like Receptor 3DL2 Binding To Aberrant HLA-B27 Heavy Chains In Spondyloarthritis
H. Hatano¹, J. Shaw¹, K McHugh², P. Bowness¹ and S. Kollnberger¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: KIR3DL2 is a Killer cell Immunoglobulin-like Receptor which binds to HLA class I including HLA-B27 (B27) β2m-free heavy chains (FHC) and HLA-A3/A11. KIR3DL2 is…
Abstract Number: 726 • 2013 ACR/ARHP Annual Meeting
Tofacitinib Does Not Inhibit Dendritic Cell Maturation and T Cell Proliferation In Vitro
Emmanuelle Le Bras^1,2, Dagmar Halbritter³ and Martin Fleck^2,4, ¹Internal Medicine I, University Medical Center of Regensburg, Regensburg 93053, Germany, ²Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ³Internal Medicine I, University Medical Center of Regensburg, 93042 Regensburg, Germany, ⁴Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany
Background/Purpose: Tofacitinib is the first approved Janus Kinase (JAK) Inhibitor for the treatment of rheumatoid arthritis (RA). The JAK/STAT pathway-inhibition leads to dysfunction of several…
Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Jayesh Pandya¹, Ingela M. Loell², Mohammad Shahadat Hossain², Mei Zong², Sukanya Raghavan², Ingrid E. Lundberg³ and Vivianne Malmström², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].